Sanofi aims for acne vaccine in new pact

Lured by the $3 billion acne treatment market, Sanofi Pasteur has inked a collaboration deal with with the University of California, San Diego to develop an immunological approach to fighting the skin condition.

Current treatments for acne use benzoyl peroxide and oral or topical antibiotics, which the company notes can disrupt the skin's balance and lead to more resistant forms of the bacteria. The collaboration will attempt to develop a vaccine that will neutralize Propionibacterium acnes factors in inflammation. Financial details of the two-year agreement weren't disclosed.

"This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," noted Dr. Elias Zerhouni, president of Global R&D, in a release. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

- here's the Sanofi release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.